176 related articles for article (PubMed ID: 33384390)
1. Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance.
Hafeez S; Webster A; Hansen VN; McNair HA; Warren-Oseni K; Patel E; Choudhury A; Creswell J; Foroudi F; Henry A; Kron T; McLaren DB; Mitra AV; Mostafid H; Saunders D; Miles E; Griffin C; Lewis R; Hall E; Huddart R
BMJ Open; 2020 Dec; 10(12):e041005. PubMed ID: 33384390
[TBL] [Abstract][Full Text] [Related]
2. Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance.
Hafeez S; Patel E; Webster A; Warren-Oseni K; Hansen V; McNair H; Miles E; Lewis R; Hall E; Huddart R
BMJ Open; 2020 May; 10(5):e037134. PubMed ID: 32461298
[TBL] [Abstract][Full Text] [Related]
3. Study Protocol of the Bladder Adjuvant RadioTherapy (BART) Trial: A Randomised Phase III Trial of Adjuvant Radiotherapy Following Cystectomy in Bladder Cancer.
Murthy V; Maitre P; Singh M; Pal M; Arora A; Pujari L; Kapoor A; Pandey H; Sharma R; Gudipudi D; Joshi A; Prabhash K; Noronha V; Menon S; Mehta P; Bakshi G; Prakash G
Clin Oncol (R Coll Radiol); 2023 Sep; 35(9):e506-e515. PubMed ID: 37208232
[TBL] [Abstract][Full Text] [Related]
4. A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial.
Hudson EM; Noutch S; Brown S; Adapala R; Bach SP; Burnett C; Burrage A; Gilbert A; Hawkins M; Howard D; Jefford M; Kochhar R; Saunders M; Seligmann J; Smith A; Teo M; Webb EJ; Webster A; West N; Sebag-Montefiore D; Gollins S; Appelt AL
BMJ Open; 2022 Apr; 12(4):e049119. PubMed ID: 35487526
[TBL] [Abstract][Full Text] [Related]
5. Adaptive Radiotherapy for Carcinoma of the Urinary Bladder: Long-term Outcomes With Dose Escalation.
Murthy V; Gupta P; Baruah K; Krishnatry R; Joshi A; Prabhash K; Noronha V; Menon S; Pal M; Prakash G; Bakshi G
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):646-652. PubMed ID: 31301959
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer.
Huddart R; Hafeez S; Lewis R; McNair H; Syndikus I; Henry A; Staffurth J; Dewan M; Vassallo-Bonner C; Moinuddin SA; Birtle A; Horan G; Rimmer Y; Venkitaraman R; Khoo V; Mitra A; Hughes S; Gibbs S; Kapur G; Baker A; Hansen VN; Patel E; Hall E;
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):412-424. PubMed ID: 33316362
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
Heer R; Lewis R; Duncan A; Penegar S; Vadiveloo T; Clark E; Yu G; Mariappan P; Cresswell J; McGrath J; N'Dow J; Nabi G; Mostafid H; Kelly J; Ramsay C; Lazarowicz H; Allan A; Breckons M; Campbell K; Campbell L; Feber A; McDonald A; Norrie J; Orozco-Leal G; Rice S; Tandogdu Z; Taylor E; Wilson L; Vale L; MacLennan G; Hall E
Health Technol Assess; 2022 Oct; 26(40):1-144. PubMed ID: 36300825
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
Fonteyne V; Dirix P; Junius S; Rammant E; Ost P; De Meerleer G; Swimberghe M; Decaestecker K
BMC Cancer; 2017 May; 17(1):308. PubMed ID: 28464906
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
Choudhury A; Porta N; Hall E; Song YP; Owen R; MacKay R; West CML; Lewis R; Hussain SA; James ND; Huddart R; Hoskin P;
Lancet Oncol; 2021 Feb; 22(2):246-255. PubMed ID: 33539743
[TBL] [Abstract][Full Text] [Related]
10. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
Huddart RA; Birtle A; Maynard L; Beresford M; Blazeby J; Donovan J; Kelly JD; Kirkbank T; McLaren DB; Mead G; Moynihan C; Persad R; Scrase C; Lewis R; Hall E
BJU Int; 2017 Nov; 120(5):639-650. PubMed ID: 28453896
[TBL] [Abstract][Full Text] [Related]
11. Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.
Hafeez S; Warren-Oseni K; McNair HA; Hansen VN; Jones K; Tan M; Khan A; Harris V; McDonald F; Lalondrelle S; Mohammed K; Thomas K; Thompson A; Kumar P; Dearnaley D; Horwich A; Huddart R
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1022-30. PubMed ID: 27026308
[TBL] [Abstract][Full Text] [Related]
12. EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial.
Akdemir E; Sweegers MG; Vrieling A; Rundqvist H; Meijer RP; Leliveld-Kors AM; van der Heijden AG; Rutten VC; Koldewijn EL; Bos SD; Wijburg CJ; Marcelissen TAT; Bongers BC; Retèl VP; van Harten WH; May AM; Groen WG; Stuiver MM
BMJ Open; 2023 Mar; 13(3):e071304. PubMed ID: 36882246
[TBL] [Abstract][Full Text] [Related]
13. Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
Huddart R; Hafeez S; Omar A; Alonzi R; Birtle A; Cheung KC; Choudhury A; Foroudi F; Gribble H; Henry A; Hilman S; Hindson B; Lewis R; Muthukumar D; McLaren DB; McNair H; Nikapota A; Olorunfemi A; Parikh O; Philipps L; Rimmer Y; Syndikus I; Tolentino A; Varughese M; Vassallo-Bonner C; Webster A; Griffin C; Hall E
Clin Oncol (R Coll Radiol); 2023 Sep; 35(9):586-597. PubMed ID: 37225552
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial.
Fonteyne V; Dirix P; Van Praet C; Berghen C; Albersen M; Junius S; Liefhooghe N; Noé L; De Meerleer G; Ost P; Villeirs G; Verbeke S; De Maeseneer D; Rammant E; Verghote F; Elhaseen E; De Man K; Decaestecker K
Eur Urol Focus; 2022 Sep; 8(5):1238-1245. PubMed ID: 34893458
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP
BMJ Open; 2023 Jun; 13(6):e065010. PubMed ID: 37321815
[TBL] [Abstract][Full Text] [Related]
17. Normal tissue sparing in a phase II trial on daily adaptive plan selection in radiotherapy for urinary bladder cancer.
Vestergaard A; Muren LP; Lindberg H; Jakobsen KL; Petersen JB; Elstrøm UV; Agerbæk M; Høyer M
Acta Oncol; 2014 Aug; 53(8):997-1004. PubMed ID: 24957559
[TBL] [Abstract][Full Text] [Related]
18. Offline adaptive radiotherapy for bladder cancer using cone beam computed tomography.
Foroudi F; Wong J; Haworth A; Baille A; McAlpine J; Rolfo A; Kron T; Roxby P; Paneghel A; Williams S; Duchesne G; Tai KH
J Med Imaging Radiat Oncol; 2009 Apr; 53(2):226-33. PubMed ID: 19527372
[TBL] [Abstract][Full Text] [Related]
19. [Plan of the day adaptive radiotherapy for bladder cancer: Dosimetric and clinical results].
Cabaillé M; Gaston R; Belhomme S; Giraud A; Rouffilange J; Roubaud G; Sargos P
Cancer Radiother; 2021 Jun; 25(4):308-315. PubMed ID: 33422418
[TBL] [Abstract][Full Text] [Related]
20. Study protocol: a multicentre, prospective, phase II trial of isotoxic hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer.
Liu YE; Xue XY; Zhang R; Chen XJ; Ding YX; Liu CX; Qin YL; Li WQ; Ren XC; Lin Q
BMJ Open; 2020 Oct; 10(10):e036295. PubMed ID: 33099491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
